DOJ Slams Lilly’s Arguments for Derailing 340B Dispute Resolution

The U.S. Justice Department (DOJ) on Tuesday asked a federal district judge in Indianapolis, in a strongly worded filing, to deny drug manufacturer Eli Lilly’s motion in late January to block the 340B program’s new administrative dispute resolution (ADR) process.

On Jan. 12, Lilly and fellow manufacturers AstraZeneca and Sanofi filed separate lawsuits to block federal sanctions over their decisions to stop or impose conditions on 340B discounts on drugs dispensed by contract pharmacies. Manufacturer Novo Nordisk sued separately three days later. Lilly, AstraZeneca, and Sanofi filed suit the day before health care providers could begin filing petitions for redress over denials of 340B pricing on contract pharmacy drugs with the new 340B ADR system.

The U.S. Justice Department (DOJ) on Tuesday asked a federal district judge in Indianapolis, in a strongly worded filing, to deny drug manufacturer Eli Lilly’s motion in late January to block the 340B program’s new administrative dispute resolution (ADR) process.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.
« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report